公开(公告)号：US12187703B2

公开(公告)日：2025-01-07

申请号：US17610321

申请日：2020-05-12

Applicant: NOVARTIS AG

Inventor： Cornelius Stephen Harlacher ,  Zaixing Li ,  Liladhar Murlidhar Waykole

IPC: C07D401/12

Abstract: The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.

公开(公告)号：US10421755B2

公开(公告)日：2019-09-24

申请号：US15712279

申请日：2017-09-22

Applicant: Novartis AG

Inventor： Wolfgang Marterer ,  Mahavir Prashad ,  Edwin Bernard Villhauer ,  Liladhar Murlidhar Waykole ,  James Anthony Vivelo ,  Bertrand Sutter ,  Jean-Claude Bianchi ,  Raeann Wu ,  Denis Har ,  Piotr H. Karpinski ,  Massimo Pignone ,  Doris Stingelin ,  Eckart Buerger

IPC: C07D453/02 ,  A61K9/20 ,  A61K31/194 ,  A61K31/439 ,  C07C55/08 ,  C07C55/10 ,  C07C57/145 ,  C07C57/15 ,  C07C51/41

Abstract: The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

公开(公告)号：US20180009801A1

公开(公告)日：2018-01-11

申请号：US15712279

申请日：2017-09-22

Applicant: Novartis AG

Inventor： Wolfgang Marterer ,  Mahavir Prashad ,  Edwin Bernard Villhauer ,  Liladhar Murlidhar Waykole ,  James Anthony Vivelo ,  Bertrand Sutter ,  Jean-Claude Bianchi ,  Raeann Wu ,  Denis Har ,  Piotr H. Karpinski ,  Massimo Pignone ,  Doris Stingelin ,  Eckart Buerger

IPC: C07D453/02 ,  A61K31/439 ,  C07C55/10 ,  C07C57/145 ,  C07C51/41 ,  A61K9/20 ,  C07C57/15 ,  A61K31/194 ,  C07C55/08

Abstract: The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

公开(公告)号：US11786498B2

公开(公告)日：2023-10-17

申请号：US15737985

申请日：2015-07-02

Applicant: Novartis AG

Inventor： David Hook ,  Bin Hu ,  Florian Karl Kleinbeck ,  Ulrich Meier ,  Sibylle Mueller ,  Jean-Paul Mutz ,  Jan Schlomach ,  Paul Allen Sutton ,  Liladhar Murlidhar Waykole ,  Bernhard Wietfeld

IPC: A61K31/22 ,  A61P9/10 ,  A61P9/06 ,  A61P25/02 ,  C07C229/34 ,  A61P9/12 ,  A61P25/06 ,  A61K31/4178 ,  A61K31/423

CPC classification number: A61K31/22 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P25/02 ,  A61P25/06 ,  C07C229/34 ,  A61K31/4178 ,  A61K31/423 ,  A61K2300/00 ,  C07B2200/13

Abstract: The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester is useful in the treatment of various conditions and disorders responsive to the inhibition of neutral endopeptidases.

公开(公告)号：US20210340152A1

公开(公告)日：2021-11-04

申请号：US17371399

申请日：2021-07-09

Applicant: NOVARTIS AG

Inventor： Ying Huang ,  Bo Liu ,  Liang Mao ,  Long Wang ,  Liladhar Murlidhar Waykole ,  Lijun Zhang

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02

Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

公开(公告)号：US11135239B1

公开(公告)日：2021-10-05

申请号：US17199736

申请日：2021-03-12

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  A61K31/381 ,  C07D339/04 ,  A61K47/38 ,  A61K47/02 ,  C07C309/72

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US11091489B2

公开(公告)日：2021-08-17

申请号：US16311638

申请日：2017-06-19

Applicant: NOVARTIS AG

Inventor： Ying Huang ,  Bo Liu ,  Liang Mao ,  Long Wang ,  Liladhar Murlidhar Waykole ,  Lijun Zhang

IPC: C07D487/04 ,  A61P35/00 ,  A61P35/02 ,  A61K31/519

Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

公开(公告)号：US11590158B2

公开(公告)日：2023-02-28

申请号：US17463391

申请日：2021-08-31

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  C07C309/72 ,  A61K31/381 ,  A61K47/02 ,  A61K47/38 ,  C07D339/04

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US11548897B2

公开(公告)日：2023-01-10

申请号：US17371399

申请日：2021-07-09

Applicant: NOVARTIS AG

Inventor： Ying Huang ,  Bo Liu ,  Liang Mao ,  Long Wang ,  Liladhar Murlidhar Waykole ,  Lijun Zhang

IPC: C07D487/04 ,  A61P35/00 ,  A61P35/02 ,  A61K31/519

Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

公开(公告)号：US20220267299A1

公开(公告)日：2022-08-25

申请号：US17610321

申请日：2020-05-12

Applicant: NOVARTIS AG

Inventor： Cornelius Stephen HARLACHER ,  Zaixing LI ,  Liladhar Murlidhar Waykole

IPC: C07D401/12

Abstract: The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a N pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition CA of the present invention can be used as a medicament, in particular for the treatment of cancers.